Geron (GERN) Stock Highlights

3.49 | -4.64%

2024-12-21 03:16:15

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The companys leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug.

Statistics

Range Today

3.46 3.69

Volume Today 26.32M

Range 1 Year

1.64 5.34

Volume 1 Year 2.53B

Range 3 Year

0.99 5.34

Volume 3 Year 4.94B

Range 10 Year

0.75 6.99

Volume 10 Year 10.26B

Highlights

Market Capitalization 2.57B (mid)

Floating Shares 555.88M

Current Price 3.49

Price To Earnings -13.16

Price To Revenue 1.67K

Price To Book 9.34

Earnings Per Share -0.32

Payout Ratio 0%

Performance

Latest -4.64%

1 Month -7.18%

3 Months -26.53%

6 Months -21.57%

1 Year +54.42%

3 Years +168.46%

5 Years +145.77%

10 Years +8.72%

Benchmarks

Market Capitalization

121 / 368

Gross Profits

235 / 278

Total Revenue

262 / 300

Total Rank

319 / 368

Free Cashflow

285 / 352

Performance 5 years

50 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.